Veozah (Fezolinetant) Patent Expiration, LOE Window & CMS Spending

Veozah (Fezolinetant) by Astellas Pharma: FDA Orange Book core substance LOE 2034-03-28, 0 AB generics, $64.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN216578 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-03-28
Last Listed Patent or Exclusivity Date2034-03-28
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$64.9M
2024 Medicare Part D Spend$38.4M
2024 Medicaid Spend$26.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.